Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for resisting helicobacter pylori and application thereof

A technology of anti-helicobacter pylori and composition, which is applied in the field of medicine, can solve the problems of the same drug administration method and related medical effects, etc., to alleviate the problem of drug resistance of helicobacter pylori, with small toxic and side effects and low medical expenses Effect

Inactive Publication Date: 2020-08-18
NANJING MEDICAL UNIV
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It has been reported that linolenic acid and divalent zinc have a certain inhibitory effect on Helicobacter pylori, but the combined administration method of linolenic acid and zinc preparation of the present invention has no report on the same administration method and related medical effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for resisting helicobacter pylori and application thereof
  • Composition for resisting helicobacter pylori and application thereof
  • Composition for resisting helicobacter pylori and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] First, antibacterial in vitro: Zinc and linolenic acid are used in combination according to the molar concentration ratio of 4:1, and the minimum inhibitory concentration of zinc gluconate oral liquid and linolenic acid capsules for drug-resistant and sensitive Helicobacter pylori is 16- 32μg / mL, polyprezinc combined with linolenic acid capsules is 16-64μg / mL.

[0019] Second, in vivo treatment: The drug combination is linolenic acid capsules, zinc preparations and omeprazole. Helicobacter pylori was used to infect mice to establish an acute gastritis model, and gastritis mice were administered intragastrically once a day for 5 consecutive days. Wherein zinc and linolenic acid are used according to the molar concentration ratio of 4:1. The daily dosage includes omeprazole 138.2mg / kg, zinc gluconate oral solution or polyprezinc 13.5mg / kg (calculated based on zinc content), linolenic acid capsule 14.5mg / kg (calculated based on linolenic acid content) . Helicobacter pylo...

Embodiment 2

[0021] First, antibacterial in vitro: zinc and linolenic acid are used in combination according to the molar concentration ratio of 1:1, and the minimum inhibitory concentration of zinc gluconate oral liquid and linolenic acid capsules for drug-resistant and sensitive Helicobacter pylori is 8- 16μg / mL, polyprezinc combined with linolenic acid capsules is 16~64μg / mL.

[0022] Second, in vivo treatment: The drug combination is linolenic acid capsules, zinc preparations and omeprazole. Helicobacter pylori was used to infect mice to establish an acute gastritis model, and gastritis mice were administered intragastrically once a day for 5 consecutive days. Among them, zinc and linolenic acid are used according to the molar concentration ratio of 1:1. Daily dosage includes omeprazole 138.2mg / kg, zinc gluconate oral solution or polyprezinc 5.3mg / kg (calculated based on zinc content), linolenic acid capsule 22.7mg / kg (calculated based on linolenic acid content) . Helicobacter pylori...

Embodiment 3

[0024] First, in vitro bacteriostasis: Zinc and linolenic acid are used in combination according to the molar concentration ratio of 1:4, zinc gluconate oral liquid (or polyprezinc) and linolenic acid capsules are used in combination on drug-resistant and sensitive Helicobacter pylori. The minimum inhibitory concentration was 16-64μg / mL.

[0025] Second, in vivo treatment: The drug combination is linolenic acid capsules, zinc preparations and omeprazole. Helicobacter pylori was used to infect mice to establish an acute gastritis model, and gastritis mice were administered intragastrically once a day for 5 consecutive days. Among them, zinc and linolenic acid are used according to the molar concentration ratio of 1:4. Daily dosage includes omeprazole 138.2mg / kg, zinc gluconate oral solution or polyprezinc 1.6mg / kg (calculated based on zinc content), linolenic acid capsule 26.4mg / kg (calculated based on linolenic acid content) . Helicobacter pylori colonization in mice decreas...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a composition for resisting helicobacter pylori and the application of the composition. The composition comprises linolenic acid capsules, a zinc preparation (zinc gluconate orpolaprezinc) and a proton pump inhibitor. The pharmaceutical composition can inhibit helicobacter pylori in vivo and in vitro by combined use, has a good effect on treatment of gastritis and other related diseases caused by helicobacter pylori infection, and especially has a good effect on refractory gastritis caused by drug-resistant helicobacter pylori infection. According to the composition, helicobacter pylori infection can be cured under the condition that antibiotics are not used, the cure rate is increased, and the occurrence rate of antibiotic resistance is reduced.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a composition for resisting Helicobacter pylori and application thereof. Background technique [0002] It is reported that about half of the people in the world are infected with Helicobacter pylori (Hp). Hp infection can lead to gastritis, stomach, duodenal ulcer and lymphoproliferative gastric lymphoma and other diseases, and is related to gastric cancer and other diseases. The World Health Organization classified Hp as a class I carcinogen in 1994, and it plays a leading role in the occurrence and development of gastric cancer and other tumors. At present, the treatment plan for Hp infection recommended by the World Health Organization is triple or quadruple therapy, that is, taking proton pump inhibitors (omeprazole, etc.) Choose two kinds) or bismuth (bismuth potassium citrate, etc.) plus proton pump inhibitor plus two kinds of antibiotics. However, with the long-term ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K33/30A61P1/04A61P31/04A61K31/202A61K31/4439
CPCA61K31/202A61K31/4439A61K33/30A61P1/04A61P31/04A61K2300/00
Inventor 毕洪凯黄衍强杭旭东贾佳曾利平
Owner NANJING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com